Patents by Inventor Manmohan Reddy Leleti

Manmohan Reddy Leleti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDONE A2R ANTAGONISTS
    Publication number: 20210161898
    Abstract: Compound that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: July 26, 2019
    Publication date: June 3, 2021
    Inventors: Manmohan Reddy LELETI, Debashis MANDAL, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • AMORPHOUS FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
    Publication number: 20210139426
    Abstract: Provided herein is an amorphous form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the amorphous form of Compound 1, described herein.
    Type: Application
    Filed: November 6, 2020
    Publication date: May 13, 2021
    Inventors: Kwok YAU, Kenken LUONG, Rajinder SINGH, Yibin ZENG, Penglie ZHANG, Manmohan Reddy LELETI, Rebecca M. LUI
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 11001603
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 11, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Modulators of chemokine receptors
    Patent number: 10988464
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: April 27, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Antoni Krasinski, Manmohan Reddy Leleti, Venkat Mali, Jeffrey McMahon, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 10981944
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: April 20, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • 2-OXINDOLE COMPOUNDS
    Publication number: 20210101890
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Application
    Filed: July 17, 2020
    Publication date: April 8, 2021
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20210101880
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: July 2, 2019
    Publication date: April 8, 2021
    Inventors: Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20210002322
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: September 1, 2020
    Publication date: January 7, 2021
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos JAEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS
    Publication number: 20200405629
    Abstract: Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions comprising same, for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, are also provided.
    Type: Application
    Filed: March 8, 2019
    Publication date: December 31, 2020
    Inventors: Juan Carlos JAEN, Jenna Leigh JEFFREY, Lixia JIN, Jaroslaw KALISIAK, Joyson J. KARAKUNNEL, M.D., Kenneth V. LAWSON, Manmohan Reddy LELETI, Jay Patrick POWERS
  • CCR6 compounds
    Patent number: 10786494
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: September 29, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jaroslaw Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • 2-oxindole compounds
    Patent number: 10759789
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: September 1, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE
    Publication number: 20200222441
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: October 2, 2017
    Publication date: July 16, 2020
    Inventors: Laurent Pierre Paul DEBIEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • CAPSULE FORMULATIONS
    Publication number: 20200170957
    Abstract: The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.
    Type: Application
    Filed: November 27, 2019
    Publication date: June 4, 2020
    Inventors: Manmohan Reddy LELETI, Jay P. POWERS
  • C5aR antagonists
    Patent number: 10660897
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 26, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Kevin Lloyd Greenman, Manmohan Reddy Leleti, Yandong Li, Jay Powers, Hiroko Tanaka, Ju Yang, Yibin Zeng
  • Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists
    Patent number: 10647696
    Abstract: Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: May 12, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jay Powers, Ju Yang
  • INHIBITORS OF CXCR2
    Publication number: 20200140418
    Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:
    Type: Application
    Filed: June 12, 2019
    Publication date: May 7, 2020
    Inventors: Xi CHEN, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Viengkham Malathong, Jeffrey McMahon, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang, Venkat Mali
  • SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS
    Publication number: 20200123139
    Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
    Type: Application
    Filed: July 30, 2019
    Publication date: April 23, 2020
    Inventors: Trevor T. CHARVAT, Junfa FAN, Christopher W. LANGE, Manmohan Reddy LELETI, Yandong LI, Venkat Reddy MALI, Jeffrey P. McMAHON, Jay POWERS, Sreenivas PUNNA, Ju YANG
  • 2-OXINDOLE COMPOUNDS
    Publication number: 20200123136
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Application
    Filed: July 29, 2019
    Publication date: April 23, 2020
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20200069689
    Abstract: Compounds that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: May 3, 2018
    Publication date: March 5, 2020
    Inventors: Manmohan Reddy LELETI, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF, Rhiannon THOMAS-TRAN
  • INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION
    Publication number: 20200062797
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: November 17, 2017
    Publication date: February 27, 2020
    Inventors: Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Ehesan Ul SHARIF